Media Articles Related to Provenge (Sipuleucel-T)
Post-Docetaxel in Castration-Resistant Prostate Cancer
Source: Medscape Headlines [2013.12.16]
Castration-resistant prostate cancer patients previously treated with docetaxel can benefit from current available therapies -- even those with poor performance status.
Prostate Cancer and Prostatic Diseases
Targeting evolving cancer stem cells in prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2013.12.05]
UCLA researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.
Risk of lethal prostate cancer in overweight patients increased by genetic mutation
Source: Genetics News From Medical News Today [2013.12.04]
Obesity is associated with a worse prostate cancer prognosis among men whose tumors contain a specific genetic mutation, suggest results from a new study led by Harvard School of Public Health (HSPH), Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers.
Tasquinimod may improve survival in men with metastatic prostate cancer
Source: Bones / Orthopedics News From Medical News Today [2013.11.21]
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Aggressive prostate cancer charted by novel study
Source: Prostate / Prostate Cancer News From Medical News Today [2013.11.20]
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone.
Published Studies Related to Provenge (Sipuleucel-T)
Cancer immunotherapy: sipuleucel-T and beyond. [2011.08]
In April 2010, sipuleucel-T became the first anticancer vaccine approved by the United States Food and Drug Administration. Different from the traditional chemotherapy agents that produce widespread cytotoxicity to kill tumor cells, anticancer vaccines and immunotherapies focus on empowering the immune system to overcome the tumor.
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. [2011.07.01]
CONCLUSIONS: No significant difference in time to BF could be shown. The finding of increased PSADT in the sipuleucel-T arm is consistent with its biologic activity in ADPC. Long-term follow-up will be necessary to determine if clinically important events, such as distant failure, are affected by therapy. Treatment was generally well tolerated.
Sipuleucel-T: in metastatic castration-resistant prostate cancer. [2011.01.01]
Sipuleucel-T is an autologous active cellular immunotherapy used in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC)... infusion-related events, such as chills and fever) generally occurred within the first day after administration of sipuleucel-T and resolved within 2 days.
Cancer immunotherapy: sipuleucel-T and beyond. 
In April 2010, sipuleucel-T became the first anticancer vaccine approved by the
United States Food and Drug Administration. Different from the traditional
chemotherapy agents that produce widespread cytotoxicity to kill tumor cells,
anticancer vaccines and immunotherapies focus on empowering the immune system to
overcome the tumor.
Integrated safety data from 4 randomized, double-blind, controlled trials of
autologous cellular immunotherapy with sipuleucel-T in patients with prostate
randomized, controlled studies in patients with prostate cancer... CONCLUSIONS: Sipuleucel-T therapy in patients with prostate cancer has a side
Clinical Trials Related to Provenge (Sipuleucel-T)
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer [Recruiting]
The main purpose of this study is to determine whether ADT started before or after
sipuleucel-T leads to a better immune system response. This study will also evaluate the
safety of sipuleucel-T treatment, immune system responses over time, the characteristics of
sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402) [Recruiting]
This study is being conducted to examine the immune response generated by sipuleucel-T in
subjects previously treated with sipuleucel-T in the androgen dependent setting. The study
will also assess the safety of receiving up to 3 additional infusions of sipuleucel-T. This
is an open-label, uncontrolled, multicenter study, conducted in up to 14 clinical trial
sites. The anticipated duration of the study is approximately 6 years.
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer [Recruiting]
- Sipuleucel-T is a new treatment for advanced stage prostate cancer. It takes cells from a
person with prostate cancer and treats them in the laboratory. Then it returns the cells to
the person to help the immune system fight the cancer. Sipuleucel-T may be combined with the
drug CT-011 to boost its ability to kill cancer cells. The chemotherapy drug
cyclophosphamide will also be given, either before or after the cells are collected at the
start of the treatment.
- To test the effectiveness of Sipuleucel-T, CT-011, and cyclophosphamide for prostate
- Men at least 18 years of age who have advanced prostate cancer.
- Participants will be screened with a medical history, physical exam, blood and urine
tests, and imaging studies.
- This study has two parts, with different participants in each part. All participants
will be monitored with frequent blood tests and imaging studies.
- Part I:
- Participants will provide cells for the Sipuleucel-T treatment three times. The first
time will be 3 days before the chemotherapy. The second time will be 10 days after
chemotherapy. The third time will be 24 days after chemotherapy.
- Participants will have one dose of cyclophosphamide the day before the first dose of
- Participants will have Sipuleucel-T about 3 days after each cell donation.
- Part II:
- Participants will be in three groups: Sipuleucel-T given alone, given with CT-011, or
given with both cyclophosphamide and CT-011.
- Participants will provide cells for the Sipuleucel-T treatment three times, as in Part
- Participants will have Sipuleucel-T about 3 days after each cell donation, and will
receive treatment with the other drugs as directed by the study doctors.
Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) [Recruiting]
The purpose of this study is to evaluate the impact of concurrent versus sequential
administration of abiraterone acetate plus prednisone on product parameters of sipuleucel-T,
and to assess the safety and efficacy of sipuleucel-T with concurrent or sequential
administration of abiraterone acetate plus prednisone in men with metastatic castrate
resistant prostate cancer.
Sipuleucel-T Manufacturing Demonstration Study [Recruiting]
To demonstrate that sipuleucel-T can be successfully manufactured for subjects with
metastatic castrate resistant prostate cancer (mCRPC) at a European manufacturing facility.
Reports of Suspected Provenge (Sipuleucel-T) Side Effects
Disease Progression (31),
Dehydration (26), more >>